Atossa Genetics Inc. (NASDAQ:ATOS) Receives Average Rating of “Hold” from Analysts

Shares of Atossa Genetics Inc. (NASDAQ:ATOS) have received an average rating of “Hold” from the five research firms that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $95.00.

A number of research firms recently weighed in on ATOS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Atossa Genetics in a research report on Wednesday, January 21st. Ascendiant Capital Markets lifted their target price on shares of Atossa Genetics from $116.25 to $120.00 and gave the company a “buy” rating in a report on Monday, December 8th.

Hedge Funds Weigh In On Atossa Genetics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ATOS. Ameriprise Financial Inc. purchased a new position in shares of Atossa Genetics during the 2nd quarter worth approximately $2,468,000. Renaissance Technologies LLC grew its holdings in Atossa Genetics by 33.2% during the fourth quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock worth $1,217,000 after acquiring an additional 514,175 shares during the period. Jane Street Group LLC purchased a new position in Atossa Genetics in the second quarter worth $381,000. Y Intercept Hong Kong Ltd acquired a new stake in Atossa Genetics in the second quarter valued at $321,000. Finally, Qube Research & Technologies Ltd lifted its holdings in Atossa Genetics by 357.4% in the second quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock valued at $346,000 after acquiring an additional 325,340 shares during the period. Institutional investors and hedge funds own 12.74% of the company’s stock.

Atossa Genetics Trading Down 5.9%

Shares of ATOS stock opened at $3.96 on Tuesday. The company has a market capitalization of $34.10 million, a P/E ratio of -1.10 and a beta of 1.36. The business’s 50 day moving average is $8.08 and its two-hundred day moving average is $11.04. Atossa Genetics has a twelve month low of $3.76 and a twelve month high of $19.35.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.